Overview

QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine

Status:
Active, not recruiting

Trial end date:
2021-12-30

Target enrollment:

Participant gender:

Summary

QUILT 3.071 NANT Colorectal Cancer (CRC) Vaccine: Phase 1b/2 NANT CRC Vaccine vs Regorafenib in Subjects with CRC Who have Previously Treated with SOC.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

ImmunityBio, Inc.
NantKwest, Inc.

Treatments:

Albumin-Bound Paclitaxel
Avelumab
Capecitabine
Cetuximab
Cyclophosphamide
Doxorubicin
Fluorouracil
Leucovorin
Oxaliplatin
Paclitaxel
Trastuzumab
Vaccines